FLT3-directed chimeric antigen receptor gamma delta T cells

FLT3-directed chimeric antigen receptor gamma delta T cells are an investigational "off-the-shelf" cellular immunotherapy designed for the treatment of acute myeloid leukemia (AML). This therapy utilizes gamma delta (γδ) T cells, which possess major histocompatibility complex (MHC)-independent tumor recognition capabilities and a lower risk of graft-versus-host disease (GvHD) compared to traditional alpha-beta (αβ) T cells. The cells are engineered with a chimeric antigen receptor (CAR) that specifically targets Fms-like tyrosine kinase 3 (FLT3), a protein frequently overexpressed or mutated in AML. To enhance persistence and anti-tumor efficacy, some variants of these cells are further modified to co-express cytokines such as IL-2 or IL-7, which have been shown in preclinical models to improve cytotoxicity and sustain stem cell-like memory T cell subsets.

Other names

FLT3-targeted CAR-γδT cellsFLT3-CAR-gamma delta T cellsFLT-3-CAR-gamma delta T cellsFLT 3-CAR-gamma delta T cellsFLT3-targeted CAR-gamma delta T cellsFLT-3-targeted CAR-gamma delta T cellsFLT 3-targeted CAR-gamma delta T cells